2003
Doxorubicin cardiotoxicity: Prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era
Mitani I, Jain D, Joska TM, Burtness B, Zaret BL. Doxorubicin cardiotoxicity: Prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era. Journal Of Nuclear Cardiology 2003, 10: 132-139. PMID: 12673177, DOI: 10.1067/mnc.2003.7.Peer-Reviewed Original ResearchConceptsCongestive heart failureDoxorubicin therapyBaseline LVEFHeart failureCumulative doxorubicin doseLower baseline LVEFNormal baseline LVEFCancer-related deathCancer chemotherapeutic agentsLVEF monitoringLower LVEFDoxorubicin doseCardiac functionDoxorubicin chemotherapySerious toxicityLower incidenceEquilibrium radionuclideLVEFHigh incidenceERNA studiesAdditional casesChemotherapeutic agentsCancer typesPatientsTherapy
2001
Use of paclitaxel in patients with pre‐existing cardiomyopathy: A review of our experience
Gollerkeri A, Harrold L, Rose M, Jain D, Burtness B. Use of paclitaxel in patients with pre‐existing cardiomyopathy: A review of our experience. International Journal Of Cancer 2001, 93: 139-141. PMID: 11391633, DOI: 10.1002/ijc.1295.Peer-Reviewed Original ResearchConceptsLeft ventricular ejection fractionYale Cancer CenterPaclitaxel therapyClinic recordsDecreased LVEFCompletion of paclitaxelPre-existing cardiomyopathyPrior cardiac diseasePrior doxorubicin therapySecond-line agentsCongestive heart failureVentricular ejection fractionUse of paclitaxelEffect of paclitaxelEjection fractionHeart failureCardiac dysfunctionClinical evidenceOutpatient clinicCancer CenterCardiac toxicityDoxorubicin therapyCardiac functionRetrospective analysisMean change